Liam C Macleod1, Scott S Tykodi2, Sarah K Holt3, Jonathan L Wright4, Daniel W Lin4, Maria S Tretiakova5, Lawrence D True5, John L Gore4. 1. Department of Urology, University of Washington, Seattle, WA. Electronic address: liamcm@uw.edu. 2. Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. 3. Department of Urology, University of Washington, Seattle, WA. 4. Department of Urology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA. 5. Department of Pathology, University of Washington, Seattle, WA.
Abstract
OBJECTIVE: To evaluate population-based survival trends, compared to optimistic trial benchmarks, in metastatic renal cell carcinoma (mRCC). Advances in medical therapy for mRCC may be associated with survival improvements. Yet, targeted therapy trial results focus on patients with favorable-risk mRCC and may not be well disseminated at the population level. METHODS: Surveillance, Epidemiology, and End Results identified adult mRCC patients diagnosed between 1990 and 2009. Survival was analyzed by treatment era (cytokine, 1990-2005; targeted therapy, 2006-2009) and stratified by histology. Multivariate Cox regression identified factors independently associated with overall survival. RESULTS: We identified 14,521 eligible patients. For clear cell mRCC (N = 4149), median survival improved from 11 to 14 months before and after targeted therapy (P <.001). For RCC with sarcomatoid features (N = 608) and RCC not otherwise specified (N = 8860), survival did not change (median survival 4 months for both). For non-clear cell subtypes (N = 904), median survival improved from 7 to 9 months (P = .008). On multivariate analysis, factors associated with increased overall survival were as follows: treatment in the targeted era (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.84-0.91), clear cell histology (HR, 0.76; 95% CI, 0.73-0.80), and receipt of surgery (HR, 0.43; 95% CI, 0.41-0.46). CONCLUSION: Population-based mRCC median survival improved but to a lesser degree than that reported in clinical trials. This represents opportunity for quality improvement in histologically guided care, use of cytoreductive nephrectomy, and development of strategies for trial-ineligible, poor-risk patients.
OBJECTIVE: To evaluate population-based survival trends, compared to optimistic trial benchmarks, in metastatic renal cell carcinoma (mRCC). Advances in medical therapy for mRCC may be associated with survival improvements. Yet, targeted therapy trial results focus on patients with favorable-risk mRCC and may not be well disseminated at the population level. METHODS: Surveillance, Epidemiology, and End Results identified adult mRCC patients diagnosed between 1990 and 2009. Survival was analyzed by treatment era (cytokine, 1990-2005; targeted therapy, 2006-2009) and stratified by histology. Multivariate Cox regression identified factors independently associated with overall survival. RESULTS: We identified 14,521 eligible patients. For clear cell mRCC (N = 4149), median survival improved from 11 to 14 months before and after targeted therapy (P <.001). For RCC with sarcomatoid features (N = 608) and RCC not otherwise specified (N = 8860), survival did not change (median survival 4 months for both). For non-clear cell subtypes (N = 904), median survival improved from 7 to 9 months (P = .008). On multivariate analysis, factors associated with increased overall survival were as follows: treatment in the targeted era (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.84-0.91), clear cell histology (HR, 0.76; 95% CI, 0.73-0.80), and receipt of surgery (HR, 0.43; 95% CI, 0.41-0.46). CONCLUSION: Population-based mRCC median survival improved but to a lesser degree than that reported in clinical trials. This represents opportunity for quality improvement in histologically guided care, use of cytoreductive nephrectomy, and development of strategies for trial-ineligible, poor-risk patients.
Authors: David M Fash; Cody J Peer; Zhenwu Li; Ian J Talisman; Sima Hayavi; Florian J Sulzmaier; Joe W Ramos; Carole Sourbier; Leonard Neckers; W Douglas Figg; John A Beutler; William J Chain Journal: Bioorg Med Chem Lett Date: 2016-04-08 Impact factor: 2.823
Authors: Michele Marchioni; Marco Bandini; Raisa S Pompe; Zhe Tian; Tristan Martel; Anil Kapoor; Luca Cindolo; Francesco Berardinelli; Alberto Briganti; Shahrokh F Shariat; Luigi Schips; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2017-09-20 Impact factor: 2.370
Authors: Tracy L Rose; Allison M Deal; Bhavani Krishnan; Matthew E Nielsen; Angela B Smith; William Y Kim; Matthew I Milowsky Journal: Cancer Date: 2016-06-24 Impact factor: 6.860
Authors: William P Parker; John C Cheville; Igor Frank; Harras B Zaid; Christine M Lohse; Stephen A Boorjian; Bradley C Leibovich; R Houston Thompson Journal: Eur Urol Date: 2016-06-07 Impact factor: 20.096
Authors: Filipe L F Carvalho; Chaoyi Zheng; Kenneth Witmer; John O'neill; John H Lynch; Keith J Kowalczyk Journal: Sci Rep Date: 2019-10-24 Impact factor: 4.379